newsfilter
← Latest News
PR Newswire·

Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research

STOCKHOLM, Aug. 12, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been published in Cli